Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Prime Sciences

Has Prime Sciences received an FDA warning letter? Yes. FDA issued a warning letter dated March 31, 2026 concerning products containing cagrilintide and retatrutide and semaglutide and tirzepatide and mazdutide.

Letter facts

Letter date
March 31, 2026 (2026-03-31)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Online / Internet Pharmacy
Products named
CagrilintideGLP1-RGLP1-SGLP1-TMazdutideBAC waterReconstitution Kit
Violation categories
Unapproved new drugMisbranding

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Factual Violation Summary

FDA says the website offered unapproved injectable peptides marketed with drug claims despite research-only disclaimers; no approved applications in effect, violating FD&C Act sections 301(d) and 505(a).

Statutory Citations & Specific Allegations

  • Unapproved new drug
  • Misbranding/adulteration (301(d) introduction into interstate commerce)

More letters about Cagrilintide

Recent FDA warning letters concerning Cagrilintide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.